Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 11/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8975331 | 0.90 | ACHE (0.40) | ACHERAB9ARCE1FOLH1TERT | |
| SCHEMBL8975328 | 0.90 | ACHE (0.40) | ACHERAB9ARCE1FOLH1TERT | |
| SCHEMBL8975323 | 0.81 | DHODH (0.40) | ACHERAB9ARCE1DHODH | |
| SCHEMBL9397404 | 0.79 | ACHE (0.53) | ACHETSHRPDE10A | |
| Trifluoromethanesulfonic Acid SCHEMBL6256102 | 0.74 | KCNH2 (0.41) | ACHETERT | |
| SCHEMBL6649021 | 0.72 | ACHE (0.52) | ACHE | |
| SCHEMBL6255899 | 0.71 | MYC (0.40) | ACHEDHODHTERT | |
| SCHEMBL10476973 | 0.70 | DHODH (0.54) | RAB9ACYP3A4CYP2C8CYP2C9DHODH | |
| SCHEMBL8997331 | 0.70 | ACHE (0.44) | ACHEPDE10A | |
| SCHEMBL8997349 | 0.70 | ACHE (0.44) | ACHEPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243167-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12275708-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240254088-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-11932603-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220227711-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-11332445-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-2074101-B1 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8119422-B2 | Stable acridinium esters with fast light emission | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100099077-A1 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-04-22 | — | — | US | disclosed |
| EP-2074101-A2 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION | Siemens Healthcare Diagnostics Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008067055-A2 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243167-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | ACR, HACD3, FCGR3B | ACHE 860/4885RAB9A 1548/4885RCE1 854/4885 |
| US-20240254088-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | ACR, HACD3, FCGR3B | ACHE 860/4885RAB9A 1548/4885RCE1 854/4885 |
| US-12275708-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | ACR, HACD3, FCGR3B | ACHE 860/4885RAB9A 1548/4885RCE1 854/4885 |
| US-11332445-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | ACR, HACD3, FCGR3B | ACHE 860/4885RAB9A 1548/4885RCE1 854/4885 |
| US-20220227711-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | ACR, HACD3, FCGR3B | ACHE 860/4885RAB9A 1548/4885RCE1 854/4885 |
| US-20100099077-A1 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION | ACR, NAALAD2, CES2 | ACHE 693/4885RAB9A 2123/4885RCE1 350/4885 |
| US-11932603-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | ACR, HACD3, FCGR3B | ACHE 860/4885RAB9A 1548/4885RCE1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.